| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 41 | 2022 | 62 | 5.260 |
Why?
|
| Pancreatic Neoplasms | 46 | 2023 | 331 | 4.330 |
Why?
|
| Pancreatitis, Acute Necrotizing | 23 | 2022 | 24 | 3.750 |
Why?
|
| Pancreatectomy | 36 | 2023 | 96 | 3.520 |
Why?
|
| Carcinoma, Pancreatic Ductal | 20 | 2023 | 106 | 2.200 |
Why?
|
| Postoperative Complications | 26 | 2023 | 1202 | 1.470 |
Why?
|
| Laparoscopy | 13 | 2021 | 427 | 1.350 |
Why?
|
| Pancreatic Ducts | 11 | 2020 | 30 | 1.310 |
Why?
|
| Adenocarcinoma | 15 | 2022 | 323 | 1.300 |
Why?
|
| Drainage | 15 | 2022 | 149 | 1.130 |
Why?
|
| Retrospective Studies | 76 | 2023 | 6071 | 1.120 |
Why?
|
| Pancreatic Fistula | 10 | 2021 | 18 | 1.060 |
Why?
|
| Adenocarcinoma, Mucinous | 9 | 2019 | 30 | 1.000 |
Why?
|
| Intestinal Fistula | 3 | 2020 | 10 | 0.900 |
Why?
|
| Middle Aged | 89 | 2022 | 16317 | 0.890 |
Why?
|
| Duodenal Diseases | 2 | 2020 | 14 | 0.860 |
Why?
|
| Humans | 138 | 2023 | 59360 | 0.820 |
Why?
|
| Sphincter of Oddi Dysfunction | 3 | 2023 | 3 | 0.810 |
Why?
|
| Pancreatic Diseases | 7 | 2015 | 39 | 0.810 |
Why?
|
| Mesenteric Veins | 2 | 2020 | 11 | 0.810 |
Why?
|
| Female | 111 | 2022 | 30705 | 0.790 |
Why?
|
| Pancreatitis | 6 | 2023 | 95 | 0.770 |
Why?
|
| Aged | 66 | 2022 | 13416 | 0.740 |
Why?
|
| Gallbladder | 12 | 2007 | 33 | 0.740 |
Why?
|
| Male | 93 | 2022 | 27739 | 0.740 |
Why?
|
| Gallstones | 3 | 2020 | 24 | 0.730 |
Why?
|
| Patient Discharge | 3 | 2023 | 489 | 0.720 |
Why?
|
| Nomograms | 1 | 2020 | 12 | 0.690 |
Why?
|
| Pancreas | 7 | 2019 | 147 | 0.680 |
Why?
|
| Vascular Fistula | 1 | 2020 | 8 | 0.680 |
Why?
|
| Crohn Disease | 2 | 2020 | 106 | 0.670 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 69 | 0.670 |
Why?
|
| Adult | 60 | 2022 | 15669 | 0.670 |
Why?
|
| Patient Readmission | 7 | 2023 | 420 | 0.660 |
Why?
|
| Venous Thrombosis | 5 | 2022 | 110 | 0.640 |
Why?
|
| Cholangiocarcinoma | 8 | 2012 | 27 | 0.600 |
Why?
|
| Choledochostomy | 1 | 2018 | 3 | 0.590 |
Why?
|
| Common Bile Duct | 1 | 2018 | 19 | 0.590 |
Why?
|
| Duodenum | 1 | 2018 | 42 | 0.580 |
Why?
|
| Hepatectomy | 7 | 2022 | 60 | 0.580 |
Why?
|
| Pancreatic Cyst | 6 | 2018 | 24 | 0.580 |
Why?
|
| Treatment Outcome | 36 | 2023 | 5284 | 0.560 |
Why?
|
| Bile Duct Neoplasms | 7 | 2012 | 42 | 0.560 |
Why?
|
| Carcinoma, Papillary | 6 | 2019 | 35 | 0.540 |
Why?
|
| Incidence | 19 | 2022 | 1237 | 0.530 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 5128 | 0.490 |
Why?
|
| Debridement | 5 | 2022 | 30 | 0.480 |
Why?
|
| Palliative Care | 8 | 2017 | 214 | 0.470 |
Why?
|
| Bile Ducts, Intrahepatic | 6 | 2010 | 25 | 0.470 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2023 | 88 | 0.460 |
Why?
|
| Length of Stay | 15 | 2021 | 775 | 0.450 |
Why?
|
| Obesity | 10 | 2022 | 1166 | 0.430 |
Why?
|
| Gastroparesis | 3 | 2019 | 8 | 0.420 |
Why?
|
| Laparotomy | 3 | 2021 | 47 | 0.410 |
Why?
|
| Gallbladder Diseases | 4 | 2007 | 26 | 0.410 |
Why?
|
| Risk Factors | 20 | 2023 | 4984 | 0.410 |
Why?
|
| Survival Rate | 16 | 2020 | 802 | 0.390 |
Why?
|
| Blood Loss, Surgical | 3 | 2018 | 57 | 0.360 |
Why?
|
| Liver Diseases | 2 | 2022 | 138 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 12 | 2018 | 250 | 0.350 |
Why?
|
| Indiana | 10 | 2021 | 19 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2020 | 1526 | 0.340 |
Why?
|
| Bile | 6 | 2019 | 19 | 0.330 |
Why?
|
| Clinical Competence | 3 | 2020 | 683 | 0.330 |
Why?
|
| Surgical Wound Infection | 4 | 2023 | 110 | 0.330 |
Why?
|
| Pancreaticojejunostomy | 3 | 2017 | 5 | 0.320 |
Why?
|
| Sphincterotomy, Transduodenal | 3 | 2023 | 4 | 0.320 |
Why?
|
| Leptin | 8 | 2006 | 83 | 0.320 |
Why?
|
| Insulin Resistance | 3 | 2007 | 392 | 0.310 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 263 | 0.310 |
Why?
|
| Cholelithiasis | 4 | 2004 | 22 | 0.300 |
Why?
|
| Muscle, Smooth | 3 | 2019 | 137 | 0.300 |
Why?
|
| Gastrostomy | 3 | 2019 | 29 | 0.300 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2010 | 12 | 0.290 |
Why?
|
| Prognosis | 12 | 2020 | 1600 | 0.290 |
Why?
|
| Biliary Fistula | 2 | 2020 | 4 | 0.290 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 2337 | 0.280 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 4 | 2023 | 46 | 0.270 |
Why?
|
| Prospective Studies | 12 | 2023 | 3067 | 0.270 |
Why?
|
| Postoperative Care | 3 | 2018 | 114 | 0.270 |
Why?
|
| Splenic Artery | 2 | 2020 | 8 | 0.270 |
Why?
|
| Preoperative Care | 7 | 2017 | 180 | 0.260 |
Why?
|
| Gallbladder Neoplasms | 1 | 2006 | 16 | 0.260 |
Why?
|
| Hernia, Ventral | 2 | 2020 | 25 | 0.260 |
Why?
|
| Splenectomy | 2 | 2019 | 41 | 0.260 |
Why?
|
| Gallbladder Emptying | 5 | 2006 | 5 | 0.250 |
Why?
|
| Neuroendocrine Tumors | 2 | 2019 | 21 | 0.250 |
Why?
|
| Necrosis | 6 | 2022 | 140 | 0.240 |
Why?
|
| Logistic Models | 6 | 2020 | 1232 | 0.230 |
Why?
|
| Aneurysm, False | 2 | 2020 | 46 | 0.230 |
Why?
|
| Intestinal Obstruction | 2 | 2020 | 49 | 0.230 |
Why?
|
| Cholesterol | 8 | 2007 | 252 | 0.230 |
Why?
|
| Insulin | 3 | 2006 | 674 | 0.220 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2023 | 12 | 0.210 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2002 | 8 | 0.200 |
Why?
|
| Surgical Wound | 1 | 2023 | 10 | 0.200 |
Why?
|
| Pain, Postoperative | 3 | 2022 | 141 | 0.200 |
Why?
|
| Young Adult | 11 | 2020 | 4267 | 0.200 |
Why?
|
| Analgesia | 1 | 2022 | 30 | 0.200 |
Why?
|
| Cholangitis | 2 | 2019 | 10 | 0.200 |
Why?
|
| Pancreatitis, Chronic | 3 | 2020 | 19 | 0.200 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 452 | 0.200 |
Why?
|
| Dilatation, Pathologic | 2 | 2019 | 29 | 0.200 |
Why?
|
| Cystadenoma, Mucinous | 2 | 2017 | 5 | 0.190 |
Why?
|
| Colonic Diseases | 1 | 2022 | 34 | 0.190 |
Why?
|
| Hyperamylasemia | 1 | 2021 | 1 | 0.190 |
Why?
|
| Adolescent | 10 | 2020 | 5824 | 0.180 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 2 | 2014 | 9 | 0.180 |
Why?
|
| Patient Selection | 7 | 2019 | 464 | 0.180 |
Why?
|
| Disease Progression | 4 | 2022 | 1122 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 8 | 0.180 |
Why?
|
| Internship and Residency | 2 | 2020 | 746 | 0.180 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 7 | 0.180 |
Why?
|
| Portal Vein | 2 | 2022 | 38 | 0.180 |
Why?
|
| Surgical Mesh | 1 | 2020 | 58 | 0.170 |
Why?
|
| Lung Diseases | 1 | 2022 | 170 | 0.170 |
Why?
|
| Gastrectomy | 1 | 2020 | 37 | 0.170 |
Why?
|
| Pulmonary Embolism | 2 | 2020 | 170 | 0.170 |
Why?
|
| Wound Closure Techniques | 1 | 2020 | 7 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 4 | 2019 | 735 | 0.170 |
Why?
|
| Leukocytosis | 1 | 2019 | 11 | 0.170 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2019 | 12 | 0.170 |
Why?
|
| Amylases | 2 | 2021 | 11 | 0.170 |
Why?
|
| Peritoneal Lavage | 1 | 2019 | 4 | 0.160 |
Why?
|
| Sphincterotomy, Endoscopic | 2 | 2023 | 7 | 0.160 |
Why?
|
| Survivors | 1 | 2020 | 149 | 0.160 |
Why?
|
| Emergencies | 1 | 2020 | 111 | 0.160 |
Why?
|
| Nurse's Role | 1 | 2020 | 116 | 0.160 |
Why?
|
| Activins | 1 | 2019 | 54 | 0.160 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 200 | 0.160 |
Why?
|
| Constriction, Pathologic | 4 | 2020 | 112 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2020 | 78 | 0.160 |
Why?
|
| Lipase | 2 | 2021 | 48 | 0.160 |
Why?
|
| Biliary Tract Diseases | 1 | 2019 | 16 | 0.160 |
Why?
|
| Workload | 1 | 2019 | 118 | 0.160 |
Why?
|
| Stomach | 1 | 2019 | 83 | 0.160 |
Why?
|
| Deoxycytidine | 2 | 2017 | 40 | 0.160 |
Why?
|
| Analgesia, Epidural | 1 | 2019 | 28 | 0.160 |
Why?
|
| Time Factors | 9 | 2019 | 3617 | 0.160 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 13 | 0.160 |
Why?
|
| Cholecystokinin | 4 | 2006 | 9 | 0.150 |
Why?
|
| Clostridium Infections | 1 | 2019 | 45 | 0.150 |
Why?
|
| DNA Fingerprinting | 1 | 2018 | 6 | 0.150 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 35 | 0.150 |
Why?
|
| Dietary Carbohydrates | 3 | 2007 | 58 | 0.150 |
Why?
|
| Travel | 1 | 2018 | 37 | 0.150 |
Why?
|
| Cholecystectomy | 3 | 2007 | 31 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2022 | 687 | 0.150 |
Why?
|
| Enteral Nutrition | 2 | 2019 | 54 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 54 | 0.150 |
Why?
|
| Thrombosis | 1 | 2020 | 182 | 0.150 |
Why?
|
| Cholestasis | 2 | 1996 | 53 | 0.150 |
Why?
|
| Surgeons | 1 | 2021 | 161 | 0.150 |
Why?
|
| Gastric Bypass | 1 | 2019 | 74 | 0.150 |
Why?
|
| Survival Analysis | 6 | 2015 | 555 | 0.150 |
Why?
|
| Perioperative Care | 1 | 2019 | 76 | 0.150 |
Why?
|
| Choledocholithiasis | 1 | 2018 | 4 | 0.150 |
Why?
|
| Analgesics | 1 | 2019 | 96 | 0.150 |
Why?
|
| Cross Infection | 1 | 2019 | 149 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2020 | 300 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 277 | 0.140 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 51 | 0.140 |
Why?
|
| Medical History Taking | 1 | 2017 | 65 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 300 | 0.140 |
Why?
|
| Cholecystitis | 2 | 2007 | 27 | 0.140 |
Why?
|
| Peripheral Nerves | 1 | 2017 | 30 | 0.140 |
Why?
|
| Hepatic Duct, Common | 1 | 2017 | 7 | 0.140 |
Why?
|
| Patient Care Team | 2 | 2017 | 326 | 0.140 |
Why?
|
| Jejunum | 1 | 2017 | 14 | 0.140 |
Why?
|
| Abdominal Pain | 1 | 2018 | 94 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 141 | 0.140 |
Why?
|
| Cancer Pain | 1 | 2017 | 15 | 0.140 |
Why?
|
| Carcinoembryonic Antigen | 2 | 1999 | 32 | 0.140 |
Why?
|
| Proton Pump Inhibitors | 2 | 2015 | 34 | 0.140 |
Why?
|
| Patient Safety | 1 | 2019 | 237 | 0.140 |
Why?
|
| Anastomotic Leak | 1 | 2017 | 33 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 163 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 308 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 39 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 49 | 0.130 |
Why?
|
| Radiotherapy | 1 | 2017 | 62 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 453 | 0.130 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 937 | 0.130 |
Why?
|
| Blood Glucose | 7 | 2007 | 461 | 0.130 |
Why?
|
| Inpatients | 1 | 2018 | 291 | 0.130 |
Why?
|
| Databases, Factual | 5 | 2018 | 813 | 0.130 |
Why?
|
| Sphincter of Oddi | 3 | 2019 | 4 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 29 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 98 | 0.130 |
Why?
|
| Lipoma | 1 | 2015 | 16 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 718 | 0.130 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 461 | 0.120 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2015 | 9 | 0.120 |
Why?
|
| Financing, Organized | 1 | 2015 | 16 | 0.120 |
Why?
|
| Surgical Stapling | 1 | 2015 | 12 | 0.120 |
Why?
|
| Anti-Ulcer Agents | 1 | 2015 | 8 | 0.120 |
Why?
|
| Intubation, Gastrointestinal | 3 | 2021 | 20 | 0.120 |
Why?
|
| CA-19-9 Antigen | 3 | 2014 | 10 | 0.120 |
Why?
|
| Publications | 1 | 2015 | 28 | 0.120 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 1995 | 5 | 0.120 |
Why?
|
| Peptic Ulcer | 1 | 2015 | 20 | 0.120 |
Why?
|
| Splenic Vein | 1 | 2014 | 2 | 0.120 |
Why?
|
| Ampulla of Vater | 1 | 1995 | 12 | 0.120 |
Why?
|
| Hyperlipidemias | 2 | 2006 | 34 | 0.120 |
Why?
|
| Lymph Node Excision | 2 | 2006 | 38 | 0.120 |
Why?
|
| Cystadenoma, Serous | 2 | 2005 | 4 | 0.120 |
Why?
|
| Adenoma | 1 | 2014 | 64 | 0.110 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2014 | 1 | 0.110 |
Why?
|
| Lipids | 2 | 2007 | 300 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2014 | 4 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 521 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 220 | 0.110 |
Why?
|
| Mutation | 2 | 2019 | 2456 | 0.110 |
Why?
|
| Parasympatholytics | 1 | 2013 | 6 | 0.110 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 170 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 676 | 0.110 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2013 | 19 | 0.110 |
Why?
|
| Ultrasonography | 3 | 2020 | 459 | 0.110 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 1025 | 0.110 |
Why?
|
| Faculty, Medical | 1 | 2015 | 192 | 0.110 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 70 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2015 | 145 | 0.110 |
Why?
|
| Bile Ducts | 1 | 2012 | 21 | 0.100 |
Why?
|
| Animals | 18 | 2019 | 19651 | 0.100 |
Why?
|
| Deep Sedation | 1 | 2012 | 4 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 406 | 0.100 |
Why?
|
| Body Mass Index | 3 | 2019 | 831 | 0.100 |
Why?
|
| Body Weight | 7 | 2007 | 368 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 228 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 10 | 2007 | 3231 | 0.100 |
Why?
|
| Smoking | 1 | 2016 | 826 | 0.100 |
Why?
|
| Liver | 3 | 2012 | 797 | 0.090 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2012 | 37 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 631 | 0.090 |
Why?
|
| Nitric Oxide Synthase | 2 | 2001 | 45 | 0.090 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2001 | 20 | 0.090 |
Why?
|
| Chi-Square Distribution | 4 | 2019 | 409 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 72 | 0.090 |
Why?
|
| Reoperation | 3 | 2019 | 272 | 0.090 |
Why?
|
| Crystallization | 6 | 2007 | 97 | 0.090 |
Why?
|
| Mice | 13 | 2019 | 10292 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 1093 | 0.090 |
Why?
|
| Anastomosis, Surgical | 3 | 2020 | 107 | 0.090 |
Why?
|
| Treatment Failure | 2 | 2020 | 185 | 0.080 |
Why?
|
| Robotics | 1 | 2010 | 69 | 0.080 |
Why?
|
| Dietary Fats | 2 | 2007 | 173 | 0.080 |
Why?
|
| Social Class | 1 | 2010 | 122 | 0.080 |
Why?
|
| Endosonography | 3 | 2017 | 26 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 18 | 0.080 |
Why?
|
| Bile Ducts, Extrahepatic | 2 | 2006 | 3 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 355 | 0.080 |
Why?
|
| Operative Time | 2 | 2019 | 76 | 0.080 |
Why?
|
| Lipid Metabolism | 2 | 2007 | 203 | 0.080 |
Why?
|
| Cholesterol, Dietary | 2 | 2006 | 28 | 0.070 |
Why?
|
| Adipose Tissue | 2 | 2007 | 283 | 0.070 |
Why?
|
| Risk Assessment | 5 | 2019 | 1921 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 674 | 0.070 |
Why?
|
| Cholangitis, Sclerosing | 2 | 1999 | 12 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2007 | 44 | 0.070 |
Why?
|
| Azetidines | 1 | 2007 | 7 | 0.070 |
Why?
|
| Morbidity | 2 | 2020 | 112 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2007 | 34 | 0.070 |
Why?
|
| Statistics, Nonparametric | 4 | 2009 | 206 | 0.070 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2007 | 2 | 0.070 |
Why?
|
| Resistin | 1 | 2007 | 6 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2019 | 327 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 31 | 0.070 |
Why?
|
| Fibroblasts | 2 | 2019 | 377 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 902 | 0.070 |
Why?
|
| Midwestern United States | 1 | 2006 | 24 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 50 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 326 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2021 | 841 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 61 | 0.060 |
Why?
|
| United States | 4 | 2020 | 7390 | 0.060 |
Why?
|
| Gene Expression | 2 | 2019 | 809 | 0.060 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 266 | 0.060 |
Why?
|
| Mice, Obese | 4 | 2006 | 80 | 0.060 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 27 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1051 | 0.060 |
Why?
|
| Dissection | 1 | 2005 | 45 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 192 | 0.060 |
Why?
|
| Cystadenoma | 1 | 2004 | 6 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2005 | 77 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 2060 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2011 | 2374 | 0.060 |
Why?
|
| Pylorus | 1 | 2004 | 10 | 0.060 |
Why?
|
| Acetylcholine | 4 | 2006 | 41 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 57 | 0.060 |
Why?
|
| Adenoma, Islet Cell | 1 | 2003 | 4 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2017 | 61 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 75 | 0.050 |
Why?
|
| Recurrence | 3 | 2014 | 603 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 1479 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 516 | 0.050 |
Why?
|
| Carcinoma | 1 | 2004 | 115 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 43 | 0.050 |
Why?
|
| Stents | 1 | 2007 | 461 | 0.050 |
Why?
|
| Muscle Contraction | 2 | 2019 | 197 | 0.050 |
Why?
|
| Diet | 1 | 2006 | 497 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2004 | 515 | 0.050 |
Why?
|
| Acute Disease | 1 | 2023 | 660 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1306 | 0.050 |
Why?
|
| Ileum | 1 | 2001 | 20 | 0.050 |
Why?
|
| Organ Size | 3 | 2007 | 164 | 0.050 |
Why?
|
| Decompression | 1 | 2021 | 1 | 0.050 |
Why?
|
| Gastric Emptying | 1 | 2021 | 6 | 0.050 |
Why?
|
| North America | 2 | 2012 | 106 | 0.050 |
Why?
|
| Gastric Fistula | 1 | 2020 | 4 | 0.040 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2020 | 7 | 0.040 |
Why?
|
| Splanchnic Circulation | 1 | 2020 | 16 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 144 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2020 | 26 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 83 | 0.040 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 34 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 847 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 396 | 0.040 |
Why?
|
| Genotype | 1 | 2002 | 617 | 0.040 |
Why?
|
| Triglycerides | 3 | 2007 | 231 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 126 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 69 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 46 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 97 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2022 | 745 | 0.040 |
Why?
|
| Heparin | 1 | 2020 | 111 | 0.040 |
Why?
|
| Efficiency | 1 | 2019 | 37 | 0.040 |
Why?
|
| Cachexia | 1 | 2019 | 9 | 0.040 |
Why?
|
| Activin Receptors, Type II | 1 | 2019 | 9 | 0.040 |
Why?
|
| Colectomy | 1 | 2020 | 104 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 170 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2019 | 33 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 36 | 0.040 |
Why?
|
| Actuarial Analysis | 2 | 1999 | 17 | 0.040 |
Why?
|
| Lymphoma | 1 | 2000 | 99 | 0.040 |
Why?
|
| Muscular Atrophy | 1 | 2019 | 25 | 0.040 |
Why?
|
| Failure to Thrive | 1 | 2019 | 7 | 0.040 |
Why?
|
| Centralized Hospital Services | 1 | 2018 | 5 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 103 | 0.040 |
Why?
|
| Genes, ras | 1 | 1998 | 27 | 0.040 |
Why?
|
| Nurses | 1 | 2020 | 102 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 326 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 1137 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2020 | 271 | 0.040 |
Why?
|
| Genes, p53 | 1 | 1998 | 52 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2019 | 87 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 32 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 65 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1504 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 161 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2020 | 134 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 477 | 0.040 |
Why?
|
| Progesterone | 1 | 1999 | 158 | 0.040 |
Why?
|
| Interstitial Cells of Cajal | 1 | 2017 | 2 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2017 | 5 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2019 | 126 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2017 | 18 | 0.040 |
Why?
|
| Stem Cell Factor | 1 | 2017 | 26 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 146 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 470 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 79 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 483 | 0.040 |
Why?
|
| Anoctamin-1 | 1 | 2017 | 16 | 0.040 |
Why?
|
| Conversion to Open Surgery | 1 | 2017 | 7 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2019 | 92 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 715 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 221 | 0.040 |
Why?
|
| Failure to Rescue, Health Care | 1 | 2017 | 4 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2050 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 98 | 0.030 |
Why?
|
| Random Allocation | 2 | 2012 | 192 | 0.030 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2007 | 56 | 0.030 |
Why?
|
| Phospholipids | 2 | 2007 | 78 | 0.030 |
Why?
|
| Choledochal Cyst | 1 | 1996 | 3 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 446 | 0.030 |
Why?
|
| Universities | 1 | 2017 | 144 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 277 | 0.030 |
Why?
|
| Dogs | 2 | 2012 | 314 | 0.030 |
Why?
|
| Surgery Department, Hospital | 1 | 2015 | 20 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2017 | 169 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2019 | 510 | 0.030 |
Why?
|
| Neuropeptide Y | 2 | 2006 | 12 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 1370 | 0.030 |
Why?
|
| Histamine H2 Antagonists | 1 | 2015 | 10 | 0.030 |
Why?
|
| Jejunostomy | 2 | 2010 | 7 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 111 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2014 | 46 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2010 | 58 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1290 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 5 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 92 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2014 | 40 | 0.030 |
Why?
|
| Neurotransmitter Agents | 2 | 2004 | 41 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2014 | 76 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2004 | 95 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2017 | 416 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 2006 | 400 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 179 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1465 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 1561 | 0.020 |
Why?
|
| Sciuridae | 2 | 2001 | 3 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1995 | 677 | 0.020 |
Why?
|
| Ligation | 1 | 2011 | 33 | 0.020 |
Why?
|
| Heart Failure | 1 | 2019 | 853 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2012 | 203 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 705 | 0.020 |
Why?
|
| Algorithms | 2 | 2010 | 976 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 98 | 0.020 |
Why?
|
| Down-Regulation | 2 | 2001 | 306 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 55 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 525 | 0.020 |
Why?
|
| Florida | 1 | 2010 | 42 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2001 | 584 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 589 | 0.020 |
Why?
|
| Contraindications | 1 | 2009 | 46 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 2902 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 306 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2009 | 127 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 297 | 0.020 |
Why?
|
| Poverty | 1 | 2010 | 281 | 0.020 |
Why?
|
| Ezetimibe | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cholesterol Esters | 1 | 2007 | 10 | 0.020 |
Why?
|
| Viscera | 1 | 2007 | 10 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 74 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 60 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2007 | 88 | 0.020 |
Why?
|
| Cholinergic Agents | 1 | 2006 | 9 | 0.020 |
Why?
|
| Decision Making | 1 | 2010 | 395 | 0.020 |
Why?
|
| Angiography | 1 | 2007 | 146 | 0.020 |
Why?
|
| Comorbidity | 1 | 2010 | 1078 | 0.020 |
Why?
|
| Butter | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiography, Interventional | 1 | 2007 | 72 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 179 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 2005 | 18 | 0.020 |
Why?
|
| Enema | 1 | 2005 | 12 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 297 | 0.010 |
Why?
|
| Spleen | 1 | 2005 | 480 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 1137 | 0.010 |
Why?
|
| Vacuoles | 1 | 2003 | 26 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 912 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2003 | 100 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 806 | 0.010 |
Why?
|
| Contrast Media | 1 | 2005 | 408 | 0.010 |
Why?
|
| Receptors, Vasoactive Intestinal Peptide | 1 | 2001 | 1 | 0.010 |
Why?
|
| Nitroarginine | 1 | 2001 | 2 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2001 | 6 | 0.010 |
Why?
|
| Iron, Dietary | 1 | 2001 | 9 | 0.010 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2001 | 23 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2001 | 131 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2001 | 44 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2001 | 133 | 0.010 |
Why?
|
| Vincristine | 1 | 2000 | 25 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 75 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 85 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2000 | 97 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 65 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2004 | 605 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 349 | 0.010 |
Why?
|
| West Virginia | 1 | 1998 | 6 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 402 | 0.010 |
Why?
|
| Cause of Death | 1 | 1999 | 210 | 0.010 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1999 | 95 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 1999 | 207 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 289 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 1999 | 243 | 0.010 |
Why?
|
| Child | 1 | 1999 | 4174 | 0.010 |
Why?
|